Publications by authors named "J A Gaudino"
Article Synopsis
- - Pumariega's JAACAP editorial highlights the negative effects of US immigration policy on children's mental health, advocating for more transparent and evidence-based policy development.
- - The International Network for Epidemiology in Policy (INEP) supports the idea that children's perspectives should be included in global policy-making, emphasizing their rights and well-being.
- - The CAP-2030 initiative aims to prioritize children’s health in line with the Sustainable Development Goals (SDGs), collaborating with young activists to ensure that children’s voices are central in national and global decisions.
Article Synopsis
- - The MET receptor is crucial for various biological processes, but its dysregulation is linked to cancers like non-small cell lung cancer and renal cancer, highlighting a significant medical need for better treatment options.
- - Current MET inhibitors face challenges such as resistance and toxicity, particularly in treating brain metastases, which further emphasizes the demand for improved therapies.
- - Researchers are developing a new class of MET inhibitors designed to effectively target brain tumors and specific cancer mutations, which showed promising results in preclinical models, significantly extending survival in treated animals.
Article Synopsis
- * Enhertu is currently the only approved treatment specifically targeting HER2 mutant tumors, but existing Tyrosine Kinase Inhibitors (TKIs) often have unwanted side effects, mainly from inhibiting EGFR.
- * The objective of this research was to develop a new, potent TKI that effectively inhibits HER2 and its YVMA mutant while maintaining oral bioavailability and sparing EGFR activity.
Article Synopsis
- RAF inhibitors have improved treatment for BRAFV600-mutant cancers, but challenges like ERK signaling adaptation and poor brain penetration limit their effectiveness.
- PF-07799933 is a new, brain-penetrant, selective pan-mutant BRAF inhibitor that shows promising results in preclinical trials by inhibiting dimer signaling and maintaining wild-type ERK signaling.
- A clinical trial for PF-07799933 demonstrated it was well-tolerated and led to multiple positive responses in patients with treatment-resistant BRAF-mutant tumors, highlighting its potential as an effective therapy combined with MEK inhibitors.